Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 455

1.

AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.

Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR.

Mol Neurodegener. 2018 May 15;13(1):22. doi: 10.1186/s13024-018-0256-6.

2.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

3.

Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.

Patel TK, Holtzman DM.

J Exp Med. 2018 May 7;215(5):1267-1268. doi: 10.1084/jem.20180494. Epub 2018 Apr 23.

PMID:
29685951
4.

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ɛ4 genotype.

Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA.

Brain. 2018 Apr 17. doi: 10.1093/brain/awy103. [Epub ahead of print]

PMID:
29672664
5.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

6.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM.

J Clin Invest. 2018 May 1;128(5):2144-2155. doi: 10.1172/JCI96429. Epub 2018 Mar 30.

7.

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.

Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM; ADNI.

Alzheimers Dement. 2018 Mar 23. pii: S1552-5260(18)30031-1. doi: 10.1016/j.jalz.2018.01.012. [Epub ahead of print]

8.

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM.

Alzheimers Dement. 2018 Mar 2. pii: S1552-5260(18)30039-6. doi: 10.1016/j.jalz.2018.01.013. [Epub ahead of print]

9.

ApoE facilitates the microglial response to amyloid plaque pathology.

Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM.

J Exp Med. 2018 Apr 2;215(4):1047-1058. doi: 10.1084/jem.20171265. Epub 2018 Feb 26.

PMID:
29483128
10.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

PMID:
29397305
11.

Regulation of amyloid-β dynamics and pathology by the circadian clock.

Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES.

J Exp Med. 2018 Apr 2;215(4):1059-1068. doi: 10.1084/jem.20172347. Epub 2018 Jan 30.

PMID:
29382695
12.

Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.

Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS.

JAMA Neurol. 2018 Jan 29. doi: 10.1001/jamaneurol.2017.4719. [Epub ahead of print]

PMID:
29379963
13.

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM.

Nat Rev Neurol. 2018 Mar;14(3):168-181. doi: 10.1038/nrneurol.2017.185. Epub 2018 Jan 29. Review.

PMID:
29377010
14.

Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.

Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM.

Alzheimers Dement. 2018 May;14(5):610-616. doi: 10.1016/j.jalz.2017.11.011. Epub 2018 Jan 10.

PMID:
29328928
15.

Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T, Holtzman DM.

Neuron. 2017 Dec 6;96(5):1013-1023.e4. doi: 10.1016/j.neuron.2017.11.014.

PMID:
29216448
16.

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM.

J Prev Alzheimers Dis. 2017;4(4):236-241. doi: 10.14283/jpad.2017.36.

PMID:
29181488
17.

Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury.

Movsas TZ, Weiner RL, Greenberg MB, Holtzman DM, Galindo R.

Front Pediatr. 2017 Nov 3;5:232. doi: 10.3389/fped.2017.00232. eCollection 2017.

18.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8. Review.

PMID:
29117955
19.

Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.

Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, Parent AT, Holtzman DM, Thinakaran G.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9665-E9674. doi: 10.1073/pnas.1708568114. Epub 2017 Oct 23.

20.

TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.

Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11524-11529. doi: 10.1073/pnas.1710311114. Epub 2017 Oct 9.

21.

NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia.

Galindo R, Banks Greenberg M, Araki T, Sasaki Y, Mehta N, Milbrandt J, Holtzman DM.

Ann Clin Transl Neurol. 2017 Aug 30;4(10):722-738. doi: 10.1002/acn3.450. eCollection 2017 Oct.

22.

Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal.

Kang SS, Kurti A, Baker KE, Liu CC, Colonna M, Ulrich JD, Holtzman DM, Bu G, Fryer JD.

Hum Mol Genet. 2018 Jan 15;27(2):211-223. doi: 10.1093/hmg/ddx366.

23.

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.

Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C; Alzheimer’s Disease Neuroimaging Initiative, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM.

Nature. 2017 Sep 28;549(7673):523-527. doi: 10.1038/nature24016. Epub 2017 Sep 20.

PMID:
28959956
24.

Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.

Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Deming Y, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM; Dominantly Inherited Alzheimer Network (DIAN); Disease Neuroimaging Initiative (ADNI); NIA-LOAD family study, Harari O.

Alzheimers Dement. 2018 Feb;14(2):205-214. doi: 10.1016/j.jalz.2017.08.013. Epub 2017 Sep 21.

PMID:
28943286
25.

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O.

Immunity. 2017 Sep 19;47(3):566-581.e9. doi: 10.1016/j.immuni.2017.08.008.

PMID:
28930663
26.

Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.

Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM.

Brain. 2017 Aug 1;140(8):2104-2111. doi: 10.1093/brain/awx148.

PMID:
28899014
27.

TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.

Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M.

Cell. 2017 Aug 10;170(4):649-663.e13. doi: 10.1016/j.cell.2017.07.023.

PMID:
28802038
28.

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.

Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ.

Alzheimers Dement. 2017 Aug;13(8):841-849. doi: 10.1016/j.jalz.2017.06.2266. Epub 2017 Jul 19. Erratum in: Alzheimers Dement. 2017 Oct;13(10 ):1185.

PMID:
28734653
29.

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM.

Alzheimers Dement. 2018 Jan;14(1):62-70. doi: 10.1016/j.jalz.2017.06.2264. Epub 2017 Jul 12.

PMID:
28710906
30.

Glial contributions to neurodegeneration in tauopathies.

Leyns CEG, Holtzman DM.

Mol Neurodegener. 2017 Jun 29;12(1):50. doi: 10.1186/s13024-017-0192-x. Review.

31.

Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.

Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM.

J Exp Med. 2017 Jul 3;214(7):2163. doi: 10.1084/jem.2016212505192017c. Epub 2017 May 23. No abstract available.

32.

Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.

Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM.

Neurobiol Aging. 2017 Aug;56:25-32. doi: 10.1016/j.neurobiolaging.2017.04.004. Epub 2017 Apr 14.

PMID:
28482211
33.

Diurnal oscillation of CSF Aβ and other AD biomarkers.

Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ.

Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.

34.

Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.

Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM.

J Alzheimers Dis. 2017;58(3):675-680. doi: 10.3233/JAD-170067.

35.

Preclinical Alzheimer's disease and longitudinal driving decline.

Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC.

Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006.

36.

Elucidating the Role of TREM2 in Alzheimer's Disease.

Ulrich JD, Ulland TK, Colonna M, Holtzman DM.

Neuron. 2017 Apr 19;94(2):237-248. doi: 10.1016/j.neuron.2017.02.042. Review.

37.

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.

Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, Braunstein J, Robinson G, Keyser J, Roh J, Knapik SS, Hu Y, Holtzman DM.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaal2029. doi: 10.1126/scitranslmed.aal2029.

38.

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.

Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, Roh J, Robinson GO, Remolina Serrano J, Holtzman DM.

J Exp Med. 2017 May 1;214(5):1227-1238. doi: 10.1084/jem.20162125. Epub 2017 Apr 17. Erratum in: J Exp Med. 2017 May 23;:.

39.

Altered sleep and EEG power in the P301S Tau transgenic mouse model.

Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM.

Ann Clin Transl Neurol. 2017 Feb 15;4(3):180-190. doi: 10.1002/acn3.390. eCollection 2017 Mar.

40.

Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition.

Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G.

J Neurosci. 2017 Apr 12;37(15):4023-4031. doi: 10.1523/JNEUROSCI.3442-16.2017. Epub 2017 Mar 8.

41.

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Kauwe JS, Goate AM, Cruchaga C.

Acta Neuropathol. 2017 May;133(5):839-856. doi: 10.1007/s00401-017-1685-y. Epub 2017 Feb 28.

42.

Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Huynh TV, Davis AA, Ulrich JD, Holtzman DM.

J Lipid Res. 2017 May;58(5):824-836. doi: 10.1194/jlr.R075481. Epub 2017 Feb 27. Review.

43.

Automated selective disruption of slow wave sleep.

Ooms SJ, Zempel JM, Holtzman DM, Ju YS.

J Neurosci Methods. 2017 Apr 1;281:33-39. doi: 10.1016/j.jneumeth.2017.02.008. Epub 2017 Feb 24.

44.

Sleep in Alzheimer's Disease - Beyond Amyloid.

Holth J, Patel T, Holtzman DM.

Neurobiol Sleep Circadian Rhythms. 2017 Jan;2:4-14. doi: 10.1016/j.nbscr.2016.08.002. Epub 2016 Aug 10.

45.

Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus.

Limbrick DD Jr, Baksh B, Morgan CD, Habiyaremye G, McAllister JP 2nd, Inder TE, Mercer D, Holtzman DM, Strahle J, Wallendorf MJ, Morales DM.

PLoS One. 2017 Feb 17;12(2):e0172353. doi: 10.1371/journal.pone.0172353. eCollection 2017.

46.

APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.

Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ.

Mol Neurodegener. 2017 Jan 31;12(1):12. doi: 10.1186/s13024-017-0156-1.

47.

Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.

Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R.

Mol Neurodegener. 2017 Jan 12;12(1):3. doi: 10.1186/s13024-016-0147-7. No abstract available.

48.

Antibody Therapeutics Targeting Aβ and Tau.

Gallardo G, Holtzman DM.

Cold Spring Harb Perspect Med. 2017 Oct 3;7(10). pii: a024331. doi: 10.1101/cshperspect.a024331. Review.

PMID:
28062555
49.

Reply.

Ju YS, Holtzman DM.

Ann Neurol. 2017 Feb;81(2):322-323. doi: 10.1002/ana.24849. Epub 2017 Jan 27. No abstract available.

PMID:
28019658
50.

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.

Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R.

Mol Neurodegener. 2016 Dec 8;11(1):74. Erratum in: Mol Neurodegener. 2017 Jan 12;12 (1):3.

Supplemental Content

Loading ...
Support Center